Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537080 | PMC |
http://dx.doi.org/10.1111/pan.13980 | DOI Listing |
J Food Drug Anal
December 2024
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Non-small cell lung cancer (NSCLC) is commonly treated with tyrosine kinase inhibitors (TKIs). However, adverse events from such treatment can lead to treatment discontinuation and additional medical expenditures. Ambulatory care from oncology pharmacists in patient education and symptom management can benefit patients with NSCLC.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
January 2025
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.
J Cancer
January 2025
Department of Oncology, Geriatric Medical Center, Wuxi Second Geriatric Hospital, Wuxi Huishan Second People's Hospital, Wuxi, 214174, Jiangsu, China.
Colorectal carcinoma (CRC) is a highly prevalent and life-threatening disease with multi-stage progression, characterized by diverse molecular expression patterns at distinct stages, making treatment particularly challenging. Early detection and diagnosis of CRC are vital and can greatly benefit from the discovery of effective biomarkers. Researchers have identified novel gene signatures that play pivotal roles in specific CRC types or stages.
View Article and Find Full Text PDFBAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF). This study tested the safety, tolerability and pharmacokinetics of this novel therapeutic option. REMOTE-HF was a multicenter, double-blind, randomized, placebo-controlled, phase Ib dose-titration study with two active arms.
View Article and Find Full Text PDFNat Commun
December 2024
Earth Commons, Georgetown University, Washington, DC, USA.
Observationally-derived emissions of ozone depleting substances must be scrutinized to maintain the progress made by the Montreal Protocol in protecting the stratospheric ozone layer. Recent observations of three chlorofluorocarbons (CFCs), CFC-113, CFC-114, and CFC-115, suggest that emissions of these compounds have not decreased as expected given global reporting of their production. These emissions have been associated with hydrofluorocarbon (HFC) production, which can require CFCs as feedstocks or generate CFCs as by-products, yet emissions from these pathways have not been rigorously quantified.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!